In addition to the technical and business advisory services, the funding will be used to conduct studies and determine efficacy, selectivity and pharmacokinetics properties for the development of SGLT2 (sodium glucose transporters) inhibitors, a new class of drugs for diabetes and obesity.
Sirona Biochem is developing SGLT2 inhibitors that are responsible for glucose reabsorption from the kidneys into the bloodstream.
Sirona Biochem applies a proprietary chemistry method to stabilise these SGLT2 inhibitors, a carbohydrate-based molecule, which is typically difficult to develop.
SGLT2s inhibitors reduce the excess glucose from entering the bloodstream by releasing the glucose into the urine and may help control Type2 diabetes.